(12) **Translation of European patent specification**

(11) **NO/EP 2780039 B1**

(19) NO

NORWAY

(51) Int Cl.
A61K 47/50 (2017.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.03.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.11.29
(86)	European Application Nr.	12787111.9
(86)	European Filing Date	2012.11.07
(87)	The European Application's Publication Date	2014.09.24
(30)	Priority	2011.11.17, US, 201161561255 P 2012.07.27, US, 201261676423 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Pfizer Inc., 235 East 42nd Street, New York, NY 10017, US-USA
(72)	Inventor	DOROSKI, Matthew David, 52 Church Street Apartment 2, Mystic, Connecticut 06355, US-USA MADERNA, Andreas, 54 Pyngyp Road, Stony Point, New York 10980, US-USA O'DONNELL, Christopher John, 71 Oxford Court, Mystic, Connecticut 06355, US-USA SUBRAMANYAM, Chakrapani, 314 Great Pond Road, South Glastonbury, Connecticut 06073, US-USA VETELINO, Beth Cooper, 368 Denison Hill Road, North Stonington, Connecticut 06359, US-USA DUSHIN, Russell George, 2 Johnny Cake Hill Road, Old Lyme, Connecticut 06371, US-USA STROP, Pavel, 130 Barneson Avenue 4, San Mateo, California 94402, US-USA GRAZIANI, Edmund, Idris, 497 South Pascack Road, Chestnut Ridge, NY 10977, US-USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF**

(56) References Cited:

WO-A2-2005/081711, WO-A2-2007/008848, SVETLANA O. DORONINA ET AL: "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity", BIOCONJUGATE CHEMISTRY, vol. 17, no. 1, 1 January 2006 (2006-01-01), pages 114-124, XP055009264, ISSN: 1043-1802, DOI: 10.1021/bc0502917, DORONINA SVETLANA O ET AL: "Novel peptide linkers for highly potent antibody-auristatin conjugate", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 19, no. 10, 1 October 2008 (2008-10-01), pages 1960-1963, XP008098503, ISSN: 1043-1802, DOI: 10.1021/BC800289A [retrieved on 2008-09-20], WO-A2-2008/052187

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse med formel **I**:



I

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



R^1 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er







C_1-C_{10}-heterosyklyl, C_3-C_8-karbosykly og C_6-C_{14}-aryl, eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av -C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR', -O-(C_1-C_8alkyl),-C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

eller R^5 er



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR', -O-(C_1-C_8-alkyl), -C(O)R', -OC(O)R',-C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH,

halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R', -SR' og arylen-R', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl, C_1-C_8heterosyklyl, C_1-C_{10}alkylen-C_3-C_8heterosyklyl og aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

R^6 er hydrogen, -C_1-C_8-alkyl, -C_2-C_8-alkenyl, -C_2-C_8-alkynyl eller -C_1-C_8-haloalkyl;

R^{12} er hydrogen, C_1-C_4-alkyl, C_1-C_{10}-heterosyklyl eller C_6-C_{14}-aryl;

R^{13} er C_1-C_{10}-heterosyklyl; og

X er O.

2. Forbindelse med formel **IIa**:



IIa

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



;

R^1 er



;

Y er -C_2-C_{20}-alkylen-, -C_2-C_{20}-heteroalkylen-; -C_3-C_8-karbosyklo-, -arylen-, -C_3-C_8heterosyklo-, -C_1-C_{10}alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo)- eller-(C_3-C_8-heterosyklo)-C_1-C_{10}alkylen-;

Z er





eller -NH_2;

G er halogen, -OH, -SH eller -S-C_1-C_6-alkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring; R^5 er









C_1-C_{10}-heterosyklyl, C_3-C_8-karbosykly og C_6-C_{14}-aryl, eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av -C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR' -O-(C_1-C_8-alkyl),-C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl; eller R^5 er



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR', -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -$S(O)_2$R', -S(O)R', -OH,

halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -$S(=O)_2$R', -SR' og arylen-R', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl, C_1-C_8heterosyklyl, C_1-C_{10}alkylen-C_3-C_8heterosyklyl og aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

R^6 er hydrogen, -C_1-C_8alkyl, -C_2-C_8alkenyl, -C_2-C_8alkynyl eller -C_1-C_8haloalkyl;

R^{12} er hydrogen, C_1-C_4alkyl, C_1-C_{10}heterosyklyl eller C_6-C_{14}aryl;

R^{13} er C_1-C_{10}heterosyklyl; og

R^7 er for hver forekomst uavhengig valgt fra gruppen bestående av F, Cl, I, Br, NO_2, CN og CF_3;

R^{10} er hydrogen, -C_1-C_{10}alkyl, -C_3-C_8karbosyklyl, -aryl, -C_1-C_{10}heteroalkyl, -C_3-C_8heterosyklo, -C_1-C_{10}alkylen-aryl, -arylen-C_1-C_{10}alkyl, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo),-(C_3-C_8 karbosyklo)-C_1-C_{10}alkyl, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo), og -(C_3-C_8-heterosyklo)-C_1-C_{10}alkyl, der aryl på R_{10} omfattende aryl eventuelt er substituert med $[R_7]_h$;

h er 1, 2, 3, 4 eller 5; og

X er O.

3. Forbindelse med formel **IIIa:**



IIIa

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



R^1 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er



eller



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -$C(O)NH_2$, -C(O)NHR', -$C(O)N(R')_2$, -NHC(O)R', -$S(O)_2$R', -S(O)R', -OH, halogen, -N_3, -NH_2, -NH(R'), -$N(R')_2$, -CN, -$NHC(=NH)NH_2$, -$NHCONH_2$, -$S(=O)_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl;

R^{11} er





eller ;

Y er -C_2-C_{20}-alkylen-, -C_2-C_{20}-heteroalkylen-, C_3-C_8-karbosyklo-, -arylen-, -C_3-C_8heterosyklo-, -C_1-C_{10}alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo)- eller-(C_3-C_8-heterosyklo)-C_1-C_{10}alkylen-;

Z er





eller -NH_2;

G er halogen, -OH, -SH eller-S-C_1-C_6alkyl;

R^7 er for hver forekomst uavhengig valgt fra gruppen bestående av F, Cl, I, Br, NO_2, CN og CF_3;

h er 1, 2, 3, 4 eller 5; og

X er O.

4. Forbindelse med formel **IIb**:



IIb

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



R^1 er



Y er -C_2-C_{20}-alkylen-, -C_2-C_{20}-heteroalkylen-, -C_3-C_8-karbosyklo-, -arylen-, -C_3-C_8heterosyklo-, -C_1-C_{10}alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo)-, eller-(C_3-C_8-heterosyklo)-C_1-C_{10}alkylen-;

Z er





eller -NHL;

L er et antistoff;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk

ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring; R^5 er



C_1-C_{10}-heterosyklyl, C_3-C_8-karbosykly og C_6-C_{14}-aryl eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av -C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR' -O-(C_1-C_8alkyl),-C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

eller R^5 er



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O) R',-C_1-C_8-alkyl-

C(O)OR', -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH,

halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R', -SR' og arylen-R', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl, C_1-C_8heterosyklyl, C_1-C_{10}alkylen-C_3-C_8heterosyklyl og aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

R^6 er hydrogen, -C_1-C_8-alkyl, -C_2-C_8-alkenyl, -C_2-C_8-alkynyl eller -C_1-C_8-haloalkyl;

R^{12} er hydrogen, C_1-C_4-alkyl, C_1-C_{10}-heterosyklyl eller C_6-C_{14}-aryl;

R^{13} er C_1-C_{10}-heterosyklyl; og

X er O.

5. Forbindelse med formel **IIIb:**



IIIb

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



R^1 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og

R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er











eller



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -$C(O)NH_2$, -C(O)NHR', -$C(O)N(R')_2$, -NHC(O)R', -$S(O)_2$R', -S(O)R', -OH, halogen, -N_3, -NH_2, -NH(R'), -$N(R')_2$, -CN, -$NHC(=NH)NH_2$, -$NHCONH_2$, -$S(=O)_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl;

R^{11} er





eller ;

Y er -C_2-C_{20}-alkylen-, -C_2-C_{20}-heteroalkylen-, -C_3-C_8-karbosyklo-, -arylen-, -C_3-C_8heterosyklo-, -C_1-C_{10}alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo)- eller-(C_3-C_8 heterosyklo)-C_1-C_{10}alkylen-;

Z er





eller -NHL;

L er et antistoff;

X er O.

6. Forbindelse med formel **IIc:**



IIc

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

$R^{1'}$ er



Y er $-C_2-C_{20}$-alkylen-, $-C_2-C_{20}$-heteroalkylen-, $-C_3-C_8$-karbosyklo-, -arylen-, $-C_3-C_8$heterosyklo-, $-C_1-C_{10}$alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, $-C_1-C_{10}$alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, $-C_1-C_{10}$alkylen-(C_3-C_8heterosyklo)- eller-(C_3-C_8 heterosyklo)-C_1-C_{10}alkylen-;

Z' er





eller -NH-;

L er et antistoff;

D er fraværende;

$R^{2'}$ er hydrogen, C_1-C_8-alkyl, C_1-C_8-haloalkyl eller er fraværende hvis



er til stede;

$R^{3A'}$ og $R^{3B'}$ er en av følgende:

(i) $R^{3A'}$ er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og $R^{3B'}$ er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl, eller halogen, eller $R^{3B'}$ er C_2-C_4-alkylen og danner en mettet 5- til 6-leddet ring som angitt ved



;

eller

(ii) $R^{3A'}$ og $R^{3B'}$ sett under ett er begge C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er







C_1-C_{10}-heterosyklyl, C_3-C_8-karbosykly og C_6-C_{14}-aryl eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av -C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR' -O-(C_1-C_8alkyl),-C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

eller R^5 er



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8alkyl, -C_1-C_8alkyl-N(R')$_2$, -C_1-C_8alkyl-C(O)R', -C_1-C_8alkyl-C(O)OR', -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R', -SR' og arylen-R', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl, C_1-C_8heterosyklyl, C_1-C_{10}alkylen-C_3-C_8heterosyklyl og aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

R^6 er hydrogen, -C_1-C_8-alkyl, -C_2-C_8-alkenyl, -C_2-C_8-alkynyl eller -C_1-C_8-haloalkyl;

R^{12} er hydrogen, C_1-C_4-alkyl, C_1-C_{10}-heterosyklyl eller C_6-C_{14}-aryl;

R^{13} er C_1-C_{10}-heterosyklyl; og

X er O.

7. Forbindelse med formel **IIIc:**



IIIc

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



R^1 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er



eller



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -$C(O)NH_2$, -C(O)NHR', -$C(O)N(R')_2$, -NHC(O)R', -$S(O)_2$R', -S(O)R', -OH, halogen, -N_3, -NH_2, -NH(R'), -$N(R')_2$, -CN, -$NHC(=NH)NH_2$, -$NHCONH_2$, -$S(=O)_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl; $R^{11'}$ er



;

Y er -C_2-C_{20}-alkylen-, -C_2-C_{20}-heteroalkylen-, -C_3-C_8-karbosyklo-, -arylen-, -C_3-C_8heterosyklo-, -C_1-C_{10}alkylen-arylen-, -arylen-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8karbosyklo)-, -(C_3-C_8karbosyklo)-C_1-C_{10}alkylen-, -C_1-C_{10}alkylen-(C_3-C_8heterosyklo)-, eller-(C_3-C_8 heterosyklo)-C_1-C_{10}alkylen-;

Z' er



,



,

eller -NH-;

L er et antistoff;

X er O.

8. Forbindelse med formel **IId:**



IId

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

L er et antistoff;

[linker] er en divalent linker;

D er fraværende;

$R^{2'}$ er hydrogen, C_1-C_8-alkyl, C_1-C_8-haloalkyl eller er fraværende hvis



er til stede;

$R^{3A'}$ og $R^{3B'}$ er en av følgende:

(i) $R^{3A'}$ er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og

$R^{3B'}$ er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl, eller $R^{3B'}$ er C_2-C_4-alkylen og danner en mettet 5- til 6-leddet ring som angitt ved ;

 ;

eller

(ii) $R^{3A'}$ og $R^{3B'}$ sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring; R^5 er







C_1-C_{10}-heterosyklyl, C_3-C_8-karbosykly og C_6-C_{14}-aryl eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av -C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR' -O-(C_1-C_8alkyl),-C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

eller R^5 er



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -C_1-C_8-alkyl-N(R')$_2$, -C_1-C_8-alkyl-C(O)R', -C_1-C_8-alkyl-C(O)OR', -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -C(O)N(R')$_2$, -NHC(O)R', -S(O)$_2$R', -S(O)R', -OH, halogen, -N_3, -N(R')$_2$, -CN, -NHC(=NH)NH_2, -$NHCONH_2$, -S(=O)$_2$R', -SR' og arylen-R', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl, C_1-C_8heterosyklyl, C_1-C_{10}alkylen-C_3-C_8heterosyklyl og aryl, eller to R' kan, sammen med nitrogenet til hvilket de er festet, danne et C_1-C_{10}-heterosyklyl;

R^6 er hydrogen, -C_1-C_8-alkyl, -C_2-C_8-alkenyl, -C_2-C_8-alkynyl eller -C_1-C_8-haloalkyl;

R^{12} er hydrogen, C_1-C_4-alkyl, C_1-C_{10}-heterosyklyl eller C_6-C_{14}-aryl;

R^{13} er C_1-C_{10}-heterosyklyl; og

X er O.

9. Forbindelse med formel **IIId:**



IIId

eller et farmasøytisk akseptabelt salt eller solvat derav, hvori, uavhengig for hver forekomst,

W er



;

R^1 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^2 er hydrogen, C_1-C_8-alkyl eller C_1-C_8-haloalkyl;

R^{3A} og R^{3B} er en av følgende:

(i) R^{3A} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; og R^{3B} er C_1-C_8-alkyl, C_1-C_8-haloalkyl, C_3-C_8-karbosyklyl eller halogen; eller

(ii) R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring;

R^5 er



eller



eventuelt substituert med 1, 2, 3, 4 eller 5 grupper uavhengig valgt fra gruppen bestående av C_1-C_8-alkyl, -O-(C_1-C_8alkyl), -C(O)R', -OC(O)R',-C(O)OR', -$C(O)NH_2$, -C(O)NHR', -$C(O)N(R')_2$, -NHC(O)R', -$S(O)_2$R', -S(O)R', -OH, halogen, -N_3, -NH_2, -NH(R'), -$N(R')_2$, -CN, -$NHC(=NH)NH_2$, -$NHCONH_2$, -$S(=O)_2$R' og -SR', hvori hver R' er uavhengig valgt fra gruppen bestående av hydrogen, C_1-C_8-alkyl og usubstituert aryl;

[linker] er en divalent linker;

L er et antistoff;

X er O.

10. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-5, 7 og 9, hvori W er



.

11. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-5, 7 og 9, hvori W er



12. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-5, 7 og 9, hvori R^2 er hydrogen eller C_1-C_8-alkyl.

13. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-5, 7 og 9, hvori R^{3A} er C_1-C_8-alkyl, foretrukket metyl.

14. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-5, 7 og 9, hvori R^{3A} og R^{3B} sett under ett er enten C_2-C_8-alkylen, hvilket C_2-C_8-alkylen sett under ett med karbonet til hvilket det er bundet, danner en mettet karbosyklisk ring; eller C_1-C_8-heteroalkylen, hvilket C_1-C_8-heteroalkylen, sammen med karbonet til hvilket det er bundet, danner en mettet heterosyklisk ring.

15. Forbindelsen, saltet eller solvatet ifølge krav 14, hvori R^{3A} og R^{3B} sett under ett er - CH_2CH_2-, hvilket -CH_2CH_2- sett under ett med karbonet til hvilket det er bundet danner syklopropyl.

16. Forbindelsen, saltet eller solvatet ifølge krav 14, hvori R^{3A} og R^{3B} sett under ett er - $CH_2CH_2CH_2CH_2$-, hvilket -$CH_2CH_2CH_2CH_2$- sett under ett med karbonet til hvilket det er bundet danner syklopentyl.

17. Forbindelsen, saltet eller solvatet ifølge krav 14, hvori R^{3A} og R^{3B} sett under ett er -CH_2OCH_2-, hvilket -CH_2OCH_2- sett under ett med karbonet til hvilket det er bundet danner oksetanyl.

18. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 1-2, 4, 6 og 8, hvori R^5 er



19. Forbindelsen, saltet eller solvatet ifølge hvilke som helst av kravene 4-9, hvori antistoffet er valgt fra trastuzumab, oregovomab, edrecolomab, cetuximab, et humanisert monoklonalt antistoff til vitronektinreseptoren ($\alpha_v\beta_3$); alemtuzumab; et humanisert anti-HLA-DR-antistoff for behandling av non-Hodgkins lymfom; 1311 Lym-1; et murint anti-HLA-Dr10-antistoff for behandling av non-Hodgkins lymfom; et humanisert anti-CD2 mAb for behandling av Hodgkins sykdom eller non-Hodgkins lymfom; labetuzumab; bevacizumab; ibritumomab tiuxetan; ofatumumab; panitumumab; rituximab; tositumomab; ipilimumab; gemtuzumab; et anti-IL13-antistoff; og et anti-Notch-antistoff.

20. Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav ifølge krav 1 valgt fra:


,


,

,

,


,

,

,


,

,

,


,

,


,

,


,

,

.


,

,

 ,
 ,
 ,

 ,
 ,
 ,

 ,
 ,
 ,

 ,
 ,
 ,

 ,
 ,
 ,

 ,

 ,
 ,
 ,



,

 ,
 ,

 ,  ,

 ,

 ,  ,  ,

 ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 ,  ,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

;

og


.

21. Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav ifølge krav 1 valgt fra:


,



































 ,
 ,
 ,

 ,
 ,

 ,
 ,

 ,
 ,
 ,

 ,
 ,

 ,
 ,

 ,
 ,
 ,

 ,
 ,
 ,

 ,
 ,



og



22. Nyttelast-linker eller et antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav ifølge et hvilket som helst av kravene 2 til 9, omfattende et radikal av en forbindelse ifølge krav 20 eller 21.

23. Antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav, omfattende et radikal av en forbindelse ifølge krav 1-3.

24. Forbindelse eller et farmasøytisk akseptabelt salt eller solvat derav ifølge hvilket som helst av kravene 2 eller 3 valgt fra:



,



,



,



,





















,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,

,



,



,



,



,



,



,



,



,































































,



,



,



,



,



,



,



,



,


,


,


,


,


,


,



og


.

25. Antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav ifølge et hvilket som helst av kravene 4, 5, 7 eller 9 omfattende et radikal av en forbindelse ifølge krav 24.

26. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



27. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



28. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



29. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



30. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



31. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



32. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



33. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



34. Nyttelast-linker eller et antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav ifølge et hvilket som helst av kravene 2 til 9, omfattende et radikal av en forbindelse ifølge krav 26-33.

35. Forbindelse ifølge krav 24 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



36. Forbindelse ifølge krav 24 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



37. Forbindelse ifølge krav 24 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



38. Forbindelse ifølge krav 24 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



39. Forbindelse ifølge krav 24 eller et farmasøytisk akseptabelt salt eller solvat derav, som er



40. Antistofflegemiddelkonjugat eller et farmasøytisk akseptabelt salt eller solvat derav ifølge et hvilket som helst av kravene 4, 5, 7 eller 9, omfattende et radikal av en forbindelse ifølge krav 35-39.

41. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1-40 eller et farmasøytisk akseptabelt salt eller solvat derav og farmasøytisk akseptabel eksipient.

42. Forbindelse ifølge et hvilket som helst av kravene 1-40 eller et farmasøytisk akseptabelt salt eller solvat derav eller en farmasøytisk sammensetning ifølge krav 41, for anvendelse i behandling av kreft.